An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis

Gene Therapy

Volumn 20, Issue 11, 2013, Pages 1033-1041

  Lampe, J ^a,d   Bossow, S ^b,e   Weiland, T ^a   Smirnow, I ^a   Lehmann, R ^c   Neubert, W ^b   Bitzer, M ^a   Lauer, U M ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c Division of Clinical Chemistry and Pathobiochemistry (Central Laboratory)   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

apoptosis; cytosine deaminase; Hepatocellular carcinoma; oncolytic measles virus; suicide gene therapy

Indexed keywords

CYTOSINE DEAMINASE; DACTINOMYCIN; FLUCYTOSINE; FLUOROURACIL; ONCOLYTIC MEASLES VACCINE VIRUS; ONCOLYTIC VIRUS; PRODRUG; SUPER CYTOSINE DEAMINASE; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER TISSUE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GENE EXPRESSION; HEPATOMA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SUICIDE GENE; SUICIDE GENE THERAPY; TUMOR CELL; TUMOR XENOGRAFT;

MEASLES VIRUS;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, LIQUID; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; DRUG RESISTANCE, NEOPLASM; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TUMOR CELLS, CULTURED; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887425033     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.28     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. In. Lyon, France: International Agency for Research on Cancer; 2010, 2008.
2. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28: 3994-4005.
3. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008; 134: 379.
4. Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Therapy 2008; 15: 877-884.
5. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006; 44: 1465-1477.
6. Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines 2010; 9: 1275-1302.
7. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875-882.
8. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
9. Esolen LM, Park SW, Hardwick JM, Griffin DE. Apoptosis as a cause of death in measles virus-infected cells. J Virol 1995; 69: 3955-3958.
10. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008; 6: 529-540.
11. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-Armed measles virus can synergize with fludarabine. Cancer Res 2007; 67: 10939-10947.
12. Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007; 15: 1991-1997.
13. Sioka C, Kyritsis AP. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 2009; 63: 761-767.
14. Graepler F, Lemken ML, Wybranietz WA, Schmidt U, Smirnow I, Gross CD et al. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol 2005; 11: 6910-6919.
15. Erbs P, Regulier E, Kintz J, Leroy P, Poitevin Y, Exinger F et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000; 60: 3813-3822.
16. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13: 471-481.
17. Glazer RI, Lloyd LS. Association of cell lethality with incorporation of 5-fluorouracil and 5-fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 1982; 21: 468-473.
18. Ingraham HA, Tseng BY, Goulian M. Nucleotide levels and incorporation of 5-fluorouracil and uracil into DNA of cells treated with 5-fluorodeoxyuridine. Mol Pharmacol 1982; 21: 211-216.
19. Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK et al. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-Armed oncolytic measles virus. Cancer Gene Ther 2012; 19: 181-191.
20. Kievit E, Bershad E, Ng E, Sethna P, Dev I, Lawrence TS et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. Cancer Res 1999; 59: 1417-1421.
21. Lemken ML, Graepler F, Wolf C, Wybranietz WA, Smirnow I, Schmidt U et al. Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies. Int J Oncol 2007; 30: 1153-1161.
22. Peng KW, Facteau S, Wegman T, OKane D, Russell SJ. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527-531.
23. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 1994; 91: 8302-8306.
24. Rehm S, Deerberg F, Sickel E. [Spontaneous diseases and pathologic changes in Han: NMRI nu/nu mice]. Z Versuchstierkd 1980; 22: 309-316.
25. Wildner O, Morris JC, Vahanian NN, Ford Jr. H, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy 1999; 6: 57-62.
26. Seo E, Abei M, Wakayama M, Fukuda K, Ugai H, Murata T et al. Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration. Cancer Res 2005; 65: 546-552.
27. Ungerechts G, Frenzke ME, Yaiw KC, Miest T, Johnston PB, Cattaneo R. Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Therapy 2010; 17: 1506-1516.
28. Dingli D, Peng KW, Harvey ME, Greipp PR, OConnor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
29. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155-7165.
30. Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I et al. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Gene Therapy 2008; 15: 1024-1034.
31. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 2006; 99: 177-184.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
33. Wood LW, Shillitoe EJ. Effect of a caspase inhibitor, zVADfmk, on the inhibition of breast cancer cells by herpes simplex virus type 1. Cancer Gene Ther 2011; 18: 685-694.
34. Karber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch Pharmacol 1931; 162: 480-483.
35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.